PMID- 37575756
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230815
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 7
DP  - 2023 Jul
TI  - A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone 
      Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 
      Diabetes Mellitus.
PG  - e41746
LID - 10.7759/cureus.41746 [doi]
LID - e41746
AB  - The purpose of this study is to assess the safety and efficacy of finerenone 
      therapy in type 2 diabetes mellitus (T2DM) patients with cardiovascular and 
      chronic renal diseases. This meta-analysis assesses the efficacy and safety of 
      finerenone in the treatment of diabetic kidney disease (DKD). A comprehensive 
      search of PubMed, Embase, and Google Scholar databases was performed to identify 
      relevant randomized controlled trials (RCTs). To quantify the effects of 
      finerenone, the analysis included the estimation of aggregated mean differences 
      (MDs) and relative risks (RRs), as well as 95% confidence intervals (CIs). This 
      meta-analysis included seven double-blind trials with patients suffering from 
      chronic kidney disease (CKD) and T2D. Participants received finerenone or a 
      placebo was assigned at random. The primary efficacy outcomes were cardiovascular 
      mortality, non-fatal myocardial infarction, non-fatal stroke, hospitalization for 
      heart failure, kidney failure, a sustained 57% decrease in the estimated 
      glomerular filtration rate from baseline over four weeks, or renal death. Among 
      the 39,995 patients included in the analysis, finerenone treatment was associated 
      with a lower risk of cardiovascular and renal-related mortality compared to 
      placebo (RR = 0.86 (0.80, 0.93), p = 0.0002; I-squared statistic (I(2) ) = 0%) 
      and (RR = 0.56 (0.17, 1.82), p = 0.34; I(2 )= 0%). In addition, finerenone 
      treatment was associated with a marginally reduced risk of serious adverse events 
      (RR = 0.95 (0.92, 0.97), p = 0.0001; I(2 )= 0%), although no significant 
      difference in the overall risk of adverse events was observed between the two 
      groups (RR = 1.00 (0.99, 1.01), p = 0.56; I(2 )= 0%). This study's findings 
      suggest that finerenone administration can reduce the risk of end-stage kidney 
      disease, renal failure, cardiovascular mortality, and hospitalization. Patients 
      with both T2DM and CKD are therefore advised to consider finerenone therapy.
CI  - Copyright (c) 2023, Jyotsna et al.
FAU - Jyotsna, Fnu
AU  - Jyotsna F
AD  - Medicine, DR. B.R. (Bharatha Rathna) Ambedkar Medical College & Hospital, 
      Bengaluru, IND.
FAU - Mahfooz, Kamran
AU  - Mahfooz K
AD  - Internal Medicine, Lincoln Medical Center, New York, USA.
FAU - Patel, Tirath
AU  - Patel T
AD  - Medical Student, American University of Antigua, St. John's, ATG.
FAU - Parshant, Fnu
AU  - Parshant F
AD  - Medicine, Jinnah Sindh Medical University, Karachi, PAK.
FAU - Simran, Fnu
AU  - Simran F
AD  - Medicine, Jinnah Sindh Medical University, Karachi, PAK.
FAU - Harsha, Fnu
AU  - Harsha F
AD  - Medicine, Jinnah Sindh Medical University, Karachi, PAK.
FAU - Neha, Fnu
AU  - Neha F
AD  - Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
FAU - Jyotishna, Dev
AU  - Jyotishna D
AD  - Cardiology, TU (Tribhuvan University) Teaching Hospital, International 
      Organization for Migration, Mohali, NPL.
FAU - Mishra, Dipesh
AU  - Mishra D
AD  - Medicine, Chirayu National Hospital and Medical Institute, Kathmandu, NPL.
FAU - Subedi, Sirjana
AU  - Subedi S
AD  - Medicine, University of Medicine and Health Sciences, Basseterre, NPL.
FAU - Khatri, Mahima
AU  - Khatri M
AD  - Medicine and Surgery, Dow University of Health Sciences, Karachi, PAK.
FAU - Kumar, Satesh
AU  - Kumar S
AD  - Medicine and Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, 
      PAK.
FAU - Varrassi, Giustino
AU  - Varrassi G
AD  - Pain Medicine, Paolo Procacci Foundation, Rome, ITA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230711
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10421409
OTO - NOTNLM
OT  - cardiovascular disease
OT  - chronic kidney disease
OT  - ckd
OT  - diabetes
OT  - finerenone
OT  - meta-analysis
OT  - non-steroidal mineralocorticoid receptor antagonist
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/08/14 06:42
MHDA- 2023/08/14 06:43
PMCR- 2023/07/11
CRDT- 2023/08/14 04:33
PHST- 2023/07/06 00:00 [received]
PHST- 2023/07/11 00:00 [accepted]
PHST- 2023/08/14 06:43 [medline]
PHST- 2023/08/14 06:42 [pubmed]
PHST- 2023/08/14 04:33 [entrez]
PHST- 2023/07/11 00:00 [pmc-release]
AID - 10.7759/cureus.41746 [doi]
PST - epublish
SO  - Cureus. 2023 Jul 11;15(7):e41746. doi: 10.7759/cureus.41746. eCollection 2023 
      Jul.